Lilly scores with new RA med; Bayer trounces FTC's marketing lawsuit; NICE greenlights Zydelig in CLL, rejects Otezla for psoriasis;

> Eli Lilly & Co. ($LLY) and Incyte ($INCY) said their experimental rheumatoid arthritis drug baricitinib beat a standard therapy, methotrexate, at quashing symptoms of the disorder. Report

> Bayer beat back allegations from the Federal Trade Commission, which had sued the drugmaker over marketing claims about a dietary supplement, Phillips' Colon Health. Report

> England's cost-effectiveness watchdogs gave their final blessing to Gilead Sciences' ($GILD) leukemia drug Zydelig, but nixed Celgene's ($CELG) anti-inflammatory drug Otezla for psoriasis. Report | Report

> AstraZeneca's ($AZN) new dose of Brilinta is available in U.S. pharmacies, the company said. Release

> Merck KGaA's consumer health business is looking to Latin America for growth. Release

And Finally... Novartis ($NVS) used fitness wearables in a virtual triathlon challenge for employees. Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

Roche Canada's new innovation challenge to fight COVID-19 has an April 10 deadline and promises up to $100,000 to fund development.

Merck, Eli Lilly and Pfizer have launched or expanded volunteer programs to dedicate medical workers to the COVID-19 effort.